Viewing
News|Articles|November 16, 2026

Dazodalibep data put Sjögren screening in focus for ophthalmologists

Key Takeaways

  • In the phase 3 OASIZ-301 trial, every-4-week dazodalibep improved overall patient-reported dryness, and both dosing regimens reduced systemic disease activity vs placebo at week 48 in adults with Sjögren disease.
  • OASIZ-301 did not include ocular-specific end points, such as corneal staining or eye-specific symptom questionnaires, so the effect of dazodalibep on ocular surface disease remains unknown.
SHOW MORE

An approved systemic therapy for Sjögren disease "would make earlier identification more actionable" for ophthalmologists, Esen K. Akpek, MD, chief of the Division of Ocular Immunology at Duke University School of Medicine, told Ophthalmology Times. Her comments follow phase 3 OASIZ-301 (NCT06104124) results for dazodalibep (Amgen), an investigational systemic therapy, presented as a late-breaking abstract at ACR Convergence 2026.1 Every-4-week dosing improved patient-reported dryness, and both dosing regimens met the primary end point of reduced systemic disease activity.1

No therapy currently holds FDA approval for Sjögren disease, according to Amgen.2 "Historically, one of the barriers to pursuing a systemic diagnosis has been the lack of specific, effective treatment options," Akpek said. Rather than simply managing ocular symptoms, she said, ophthalmologists could help connect patients with multidisciplinary care.

Akpek made a related case in a July interview with Ophthalmology Times, noting ocular symptoms often precede a systemic Sjögren diagnosis by an average of a decade.3 At the time, she said "approximately 1 in 10 patients with clinically significant dry eye have underlying Sjögren disease," and half of these patients are undiagnosed at presentation.3

Which dry eye findings should prompt a Sjögren referral?

Akpek recommends a brief systemic screening questionnaire for every patient presenting with dry eye, covering medical history, personal and family history of autoimmune disease, and associated symptoms. She advised asking about dry mouth, difficulty swallowing dry foods, recurrent dental caries, salivary gland swelling, fatigue, and joint pain. She compared the approach to the detailed review of systems routinely obtained in patients presenting with uveitis.

"Importantly, consideration of Sjögren's disease should be independent of the severity of the patient's dry eye symptoms," she said. Patients with Sjögren disease may report fewer symptoms than their ocular surface damage would suggest, which she attributed partly to a neurotrophic component reducing symptom perception. "Reduced Schirmer measurements and substantial corneal fluorescein or conjunctival lissamine green staining should further raise suspicion," she added.

"A patient may present with objective signs of significant ocular surface disease long before receiving a systemic diagnosis or even recognizing that their other symptoms may be related," Akpek said.

Dazodalibep dryness outcomes and ocular end points in OASIZ-301

OASIZ-301 randomly assigned 648 adults with Sjögren disease and moderate to severe systemic disease activity to intravenous dazodalibep 1500 mg every 4 weeks (n = 217), intravenous dazodalibep 3000 mg every 12 weeks (n = 217), or placebo (n = 214).1 In the every-4-week arm, dryness scores on the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) improved by 2.50 points vs 1.33 points with placebo at week 48 (adjusted P < .001).1 Scores on the Diary for Assessing Sjögren's Patient Reported Index (DASPRI) dryness domain improved by 1.98 points vs 1.05 points (adjusted P < .001), and Amgen did not report dryness results for the every-12-week arm.1,2

Akpek cautioned against overinterpreting these results. "Although the every-four-week dazodalibep regimen improved patient-reported dryness as measured by ESSPRI, these results do not establish an improvement in ocular surface disease specifically," she said. The ESSPRI "includes only a single dryness question," she noted, and does not distinguish ocular dryness from oral or other forms.

For future trials, Akpek described corneal fluorescein and conjunctival lissamine green staining as "arguably more relevant when evaluating improvements in ocular surface health" than Schirmer testing, which she views primarily as a marker of lacrimal gland damage. She also called for validated, eye-specific patient-reported outcome measures. Scleritis, uveitis, and peripheral ulcerative keratitis "are not captured in current systemic disease activity measures," she added.

Dazodalibep systemic efficacy and safety in Sjögren disease

The primary end point was change in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), a rheumatology measure of systemic disease activity.1 At week 48, ESSDAI fell by 5.6 points with the every-4-week regimen and 5.2 points with the every-12-week regimen vs 3.8 points with placebo (adjusted P < .001 and P = .010, respectively).1

Serious adverse events and discontinuations occurred at similar rates across arms, while treatment-related adverse events were more frequent with dazodalibep (36.7% and 31.8% vs 24.9% with placebo).1 Infusion-related reactions, nasopharyngitis, urinary tract infection, and hypertension occurred more often than with placebo, according to Amgen.2

Ultimately, Akpek said, the prospect of an effective systemic treatment "makes recognizing and referring patients with suspected Sjögren's disease much more clinically consequential." Amgen's phase 3 program also includes OASIZ-303 (NCT06245408), in patients with high symptom burden and low systemic disease activity.2 The company has not announced timing for a regulatory submission.2

Frequently Asked Questions

Does dazodalibep improve dry eye in Sjögren disease?

OASIZ-301 measured overall patient-reported dryness as a key secondary end point, and every-4-week dosing improved it vs placebo. The trial did not include ocular-specific end points, such as corneal staining or eye-specific symptom questionnaires, so its effect on ocular surface disease remains unknown.

Which patients with dry eye warrant evaluation for Sjögren disease?

Akpek recommends a brief systemic screening questionnaire for every patient with dry eye, regardless of symptom severity. Reduced Schirmer scores and substantial corneal or conjunctival staining should raise suspicion.

What is dazodalibep?

Dazodalibep (Amgen) is an investigational intravenous CD40L antagonist fusion protein in phase 3 development for Sjögren disease. It does not yet have FDA approval.

References
1. Noaiseh G, Devauchelle-Pensec V, St Clair E, et al. Dazodalibep significantly reduces systemic disease activity in patients with Sjögren's disease and moderate-to-severe disease activity: results from the phase 3 OASIZ-301 trial [abstract]. Arthritis Rheumatol. 2026;78(suppl 9). Accessed November 11, 2026. https://acrabstracts.org/abstract/dazodalibep-significantly-reduces-systemic-disease-activity-in-patients-with-sjogrens-disease-and-moderate-to-severe-disease-activity-results-from-the-phase-3-oasiz-301-trial/
2. Amgen. Amgen announces positive phase 3 results for dazodalibep in Sjögren's disease. Published November 11, 2026. Accessed November 11, 2026. https://www.prnewswire.com/news-releases/amgen-announces-positive-phase-3-results-for-dazodalibep-in-sjogrens-disease-302935991.html
3. Akpek EK, Gambuzza L. Esen Akpek, MD, on dry eye quality of life, Sjögren disease, and knowing when to escalate treatment. Ophthalmology Times. Published July 12, 2026. Accessed November 11, 2026. https://www.ophthalmologytimes.com/view/esen-akpek-dry-eye-quality-ife-escalate-treatment

Related to this article